AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17936861 — intervention group
Group type: EXPERIMENTAL
Intervention: 417 kcal beverage with 95% of the calories from long-chain fatty acids
Number of subjects: 12
Study 17936861 — intervention group
Group type: COMPARATOR
Intervention: 21 kcal lipid-free control beverage
Number of subjects: 12
Study 17936861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid beverage in High PYY group
Number of subjects: 12
Study 17936861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid beverage in Low PYY group
Number of subjects: 12
Study 16417774 — intervention group
Group type: EXPERIMENTAL
Intervention: Suogudan Granule (SGDG) 6 g orally, thrice a day for 6 weeks
Number of subjects: 90
Study 16417774 — intervention group
Group type: EXPERIMENTAL
Intervention: Suogudan Granule (SGDG)
Number of subjects: 90
Study 16417774 — intervention group
Group type: COMPARATOR
Intervention: Fenbid Capsules 0.3 g twice a day and Tripterygium tablet 20 mg thrice a day for 6 weeks
Number of subjects: 90
Study 16417774 — intervention group
Group type: COMPARATOR
Intervention: Fenbid Capsules and Tripterygium tablet
Number of subjects: 90
Study 12212584 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 88
Study 12212584 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 88
Study 10472214 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 10472214 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 20
Study 8693438 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 10
Study 8693438 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 10
Study 8693438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8693438 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 10
Study 8693438 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 10
Study 8693438 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol and Formoterol
Number of subjects: 10
Study 1923078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 102
Study 1923078 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐potassium clavulanate
Number of subjects: 102
Study 1923078 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant cases
Number of subjects: 102
Study 1923078 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliant cases
Number of subjects: 102
Study 1923078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic group compliance
Number of subjects: 102
Study 7026794 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (progressive muscle relaxation training and guided relaxation imagery instructions)
Number of subjects: 0
Study 7026794 — intervention group
Group type: COMPARATOR
Intervention: No relaxation training
Number of subjects: 0
Study 7026794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 0
Study 30348960 — intervention group
Group type: EXPERIMENTAL
Intervention: ELEV (supine, bed elevated 30 degrees)
Number of subjects: 180
Study 30348960 — intervention group
Group type: COMPARATOR
Intervention: FLAT (flat, supine)
Number of subjects: 180
Study 28403531 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal rinse group (EcRg)
Number of subjects: 80
Study 28403531 — intervention group
Group type: COMPARATOR
Intervention: Circulatory rinse group (CRg)
Number of subjects: 80
Study 28403531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 25733639 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol (HF) cocoa flavanols (993 mg)
Number of subjects: 90
Study 25733639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate flavanol (IF) cocoa flavanols (520 mg)
Number of subjects: 90
Study 25733639 — intervention group
Group type: COMPARATOR
Intervention: Low flavanol (LF) cocoa flavanols (48 mg)
Number of subjects: 90
Study 24393375 — intervention group
Group type: EXPERIMENTAL
Intervention: FAIM2-rs7138803 polymorphism (AA vs G-carriers)
Number of subjects: 7161
Study 24393375 — intervention group
Group type: EXPERIMENTAL
Intervention: FAIM2-rs7138803 polymorphism (AA vs G-carriers) in type-2 diabetic subjects
Number of subjects: 7161
Study 23015619 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Supreme™
Number of subjects: 12
Study 23015619 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 12
Study 19440810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg . kg(‐1)
Number of subjects: 184
Study 19440810 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg . kg(‐1)
Number of subjects: 184
Study 17520356 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based Work Hardening (WWH)
Number of subjects: 103
Study 17520356 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based Work Hardening (CWH)
Number of subjects: 103
Study 16283605 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐Hu EPO) 750 U/kg per week subcutaneously from day 5 to 40 and enteral iron supplementation of 2 to 6 mg/kg/d beginning on day 14.
Number of subjects: 93
Study 16283605 — intervention group
Group type: COMPARATOR
Intervention: Enteral iron supplementation beginning at the end of the fourth week (control group).
Number of subjects: 93
Study 12217280 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium vaccae 1mg plus 0.02 microg Tuberculin protein per 0.1 ml dose
Number of subjects: 92
Study 12217280 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 92
Study 10220125 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (controlled release)
Number of subjects: 205
Study 10220125 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 205
Study 7824139 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAT patients (n = 61)
Number of subjects: 61
Study 7824139 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 61)
Number of subjects: 61
Study 7824139 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of SDAT patients (n = 23)
Number of subjects: 61
Study 2104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 (D1, n = 5) - 450‐550 kcal/d, protein at 1.5 g/kg IBW, less than 10 g carbohydrate (CHO)
Number of subjects: 10
Study 2104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (D2, n = 5) - 420 kcal/d formula, providing 70 g (1.2 g/kg IBW) protein and 30 g CHO
Number of subjects: 10
Study 7467379 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (higher dosage)
Number of subjects: 581
Study 7467379 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol with thiopental (3 mg/kg)
Number of subjects: 581
Study 7467379 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol with ketamine
Number of subjects: 581
Study 31537259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Number of subjects: 18178
Study 31537259 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 18178
Study 28993415 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring according to IGF-I (n=33)
Number of subjects: 84
Study 28993415 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring according to GHnadir (n=28)
Number of subjects: 84
Study 28993415 — intervention group
Group type: COMPARATOR
Intervention: Surgery group
Number of subjects: 84
Study 28993415 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 84
Study 26880251 — intervention group
Group type: EXPERIMENTAL
Intervention: Show Me My Health Plans decision support tool
Number of subjects: 362
Study 26880251 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition (healthcare.gov marketplace website)
Number of subjects: 362
Study 24420962 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD spray
Number of subjects: 303
Study 22645292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachycardia/ventricular fibrillation (VT/VF) ≤48 hours after enrollment
Number of subjects: 9211
Study 22645292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachycardia/ventricular fibrillation (VT/VF) >48 hours after enrollment
Number of subjects: 9211
Study 22645292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachycardia/ventricular fibrillation (VT/VF)
Number of subjects: 9211
Study 20644185 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Care
Number of subjects: 49
Study 20644185 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 49
Study 17227743 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica 30c, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Number of subjects: 190
Study 17227743 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Number of subjects: 190
Study 15155712 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP at doses ranging from 25 to 800 pmol
Number of subjects: 43
Study 15155712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of H1 receptors
Number of subjects: 43
Study 15155712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined H1‐receptor inhibition and NO synthase inhibition
Number of subjects: 43
Study 15155712 — intervention group
Group type: EXPERIMENTAL
Intervention: H2‐receptor inhibition
Number of subjects: 43
Study 11268267 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced transfusion
Number of subjects: 531
Study 11268267 — intervention group
Group type: COMPARATOR
Intervention: Unmodified transfusion
Number of subjects: 531
Study 9530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Videokeratography indices
Number of subjects: 241
Study 9530594 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic pachymetry measurements
Number of subjects: 241
Study 7985670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer with high reuse (mean, 13.8 uses)
Number of subjects: 436
Study 7985670 — intervention group
Group type: COMPARATOR
Intervention: Dialyzer with low reuse (mean, 3.8 uses)
Number of subjects: 436
Study 2609672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Doxepin treatment
Number of subjects: 45
Study 2609672 — intervention group
Group type: COMPARATOR
Intervention: Oral Doxepin treatment
Number of subjects: 45
Study 48000 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction of labour
Number of subjects: 111
Study 48000 — intervention group
Group type: COMPARATOR
Intervention: Control (managed expectantly until 41 weeks)
Number of subjects: 111
Study 31634766 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0
Study 31634766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28562839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer with step-count goal setting
Number of subjects: 32
Study 28562839 — intervention group
Group type: COMPARATOR
Intervention: Pedometer only
Number of subjects: 32
Study 26483357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 20 mg
Number of subjects: 12
Study 26483357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 30 mg
Number of subjects: 12
Study 26483357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 40 mg
Number of subjects: 12
Study 26483357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 5 mg
Number of subjects: 12
Study 26483357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 10 mg
Number of subjects: 12
Study 26483357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26483357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 30 mg
Number of subjects: 12
Study 23684127 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methodology using pre-treatment EEG data for predicting response to SSRI treatment
Number of subjects: 0
Study 21275593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment coverage (80%-90%)
Number of subjects: 0
Study 21275593 — intervention group
Group type: EXPERIMENTAL
Intervention: High treatment coverage (over 90%)
Number of subjects: 0
Study 21275593 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual treatment for 3 years
Number of subjects: 0
Study 21275593 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduation rule (halt treatment based on absence of follicular trachoma or infection)
Number of subjects: 0
Study 19783552 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine (1000 mg/m²) and split-dose cisplatin (40 mg/m²) administered on days 1 and 8 at 3-week intervals for four cycles.
Number of subjects: 45
Study 19783552 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine and split-dose cisplatin
Number of subjects: 45
Study 16423116 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Discovery (CD) teaching method
Number of subjects: 80
Study 16423116 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration and Practice (DP) teaching method
Number of subjects: 80
Study 16423116 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual ward teaching sessions)
Number of subjects: 80
Study 12608026 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 12658
Study 12608026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12658
Study 16571153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomatoes, tomato juice, tomato purée (12.5 mg lycopene/d for 4 weeks)
Number of subjects: 0
Study 10676542 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 0
Study 10676542 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-school partnership (FSP) intervention
Number of subjects: 0
Study 8739513 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (300 micrograms and 600 micrograms per day by nasal spray for 6 months)
Number of subjects: 0
Study 8739513 — intervention group
Group type: COMPARATOR
Intervention: IUD users (control group)
Number of subjects: 0
Study 2017313 — intervention group
Group type: EXPERIMENTAL
Intervention: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days)
Number of subjects: 20
Study 2017313 — intervention group
Group type: COMPARATOR
Intervention: calcium heparin 5,000 IU t.i.d. SC (since the day of surgery and for the following 7 days)
Number of subjects: 20
Study 7149870 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 223
Study 7149870 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 223
Study 31888883 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/min) infusion for 150 min
Number of subjects: 15
Study 31888883 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/min) + insulin (1 mU/kg/min) infusion for 120 min
Number of subjects: 15
Study 31888883 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 15
Study 31888883 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 15
Study 30566166 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food
Number of subjects: 0
Study 30566166 — intervention group
Group type: COMPARATOR
Intervention: Liquid food
Number of subjects: 0
Study 30566166 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-solid food
Number of subjects: 0
Study 29077924 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative Behavioral Therapy (BPMT)
Number of subjects: 374
Study 29077924 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 374
Study 26585724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment of anxiety before surgery
Number of subjects: 27
Study 25349296 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation of painful osseous metastases
Number of subjects: 850
Study 21790779 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 200 μg b.i.d. via AeroChamber Plus
Number of subjects: 26
Study 21790779 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate (BDP) 200 μg b.i.d. via Volumatic spacer
Number of subjects: 26
Study 21790779 — intervention group
Group type: EXPERIMENTAL
Intervention: UFC/creatinine data
Number of subjects: 26
Study 19778452 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 117
Study 19778452 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 117
Study 17437654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17437654 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.5 mg kg‐1
Number of subjects: 100
Study 17437654 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg kg‐1
Number of subjects: 100
Study 17437654 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 microg kg‐1 and Dexamethasone 0.5 mg kg‐1
Number of subjects: 100
Study 15333081 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion (Bi)
Number of subjects: 216
Study 15333081 — intervention group
Group type: COMPARATOR
Intervention: Monophasic cardioversion (Mo)
Number of subjects: 216
Study 11425511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (1g TID for 12 days)
Number of subjects: 98
Study 11425511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 days)
Number of subjects: 98
Study 9512946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 200 ml/l of ascites removed, n = 27
Number of subjects: 60
Study 9512946 — intervention group
Group type: COMPARATOR
Intervention: Albumin 8 g/l of ascites removed, n = 33
Number of subjects: 60
Study 7527326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10 to 40 mg/day
Number of subjects: 0
Study 7527326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril dosages up to 80 mg/day and/or concomitant diuretic therapy
Number of subjects: 0
Study 7527326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril titration from 10 to 40 mg/day
Number of subjects: 0
Study 7527326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril with hydrochlorothiazide
Number of subjects: 0
Study 7527326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril ≤ 40 mg/day
Number of subjects: 0
Study 7527326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study 7527326 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 7527326 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 30691753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise therapy (closed kinetic chain exercises and proprioception exercises)
Number of subjects: 24
Study 30691753 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study 28448088 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored dietary counseling for six months; instructed to increase food intake with energy-dense food items, number of meals, and consumption of energy-, protein-, and nutrient-rich snacks.
Number of subjects: 224
Study 28448088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling).
Number of subjects: 224
Study 26761968 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotriazoline (600 mg/d)
Number of subjects: 0
Study 26761968 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/d)
Number of subjects: 0
Study 23403547 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal nerve resection (group B)
Number of subjects: 40
Study 23403547 — intervention group
Group type: COMPARATOR
Intervention: Distal nerve resection (group A)
Number of subjects: 40
Study 21153445 — intervention group
Group type: EXPERIMENTAL
Intervention: Phe supplementation
Number of subjects: 9
Study 18595523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerius 5 mg/d for 12 days
Number of subjects: 75
Study 16738858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVT) 4 mg
Number of subjects: 27
Study 16738858 — intervention group
Group type: COMPARATOR
Intervention: Sham subconjunctival injection
Number of subjects: 27
Study 12900738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG), 400 microg
Number of subjects: 49
Study 12900738 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (MET), 50 mg
Number of subjects: 49
Study 12900738 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML), 5 mg
Number of subjects: 49
Study 10847214 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized self‐administered interview
Number of subjects: 0
Study 10847214 — intervention group
Group type: COMPARATOR
Intervention: Paper‐and‐pencil self‐administered interview
Number of subjects: 0
Study 10847214 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of parents during the interview
Number of subjects: 0
Study 10847214 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of siblings during the interview
Number of subjects: 0
Study 10847214 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of husband, wife, or live‐in partner during the interview
Number of subjects: 0
Study 9177526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursocholic acid (900 mg/day)
Number of subjects: 4
Study 9177526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursocholate (900 mg/day)
Number of subjects: 4
Study 9177526 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (900 mg/day) after 1 month of ursocholic acid or tauroursocholate feeding
Number of subjects: 4
Study 8415401 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered solution of didanosine
Number of subjects: 0
Study 8415401 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution of didanosine
Number of subjects: 0
Study 8415401 — intervention group
Group type: COMPARATOR
Intervention: Citrate-phosphate buffer sachet
Number of subjects: 0
Study 8415401 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablet and antacid suspension
Number of subjects: 0